Noradrenaline in mood and anxiety disorders: Basic and clinical studies

Nicoletta Brunello, Pier Blier, Lewis L. Judd, Julien Mendlewicz, Craig J. Nelson, Daniel Souery, Joseph Zohar, Giorgio Racagni

Research output: Contribution to journalReview articlepeer-review


The neurotransmitter noradrenaline is known to be involved in a range of physiological and psychological processes, and dysfunctions of this neurotransmitter system have been implicated in a range of psychiatric disorders. However, the clinical utility of targeting the noradrenergic system in the treatment of such disorders has been somewhat overshadowed by the availability of agents selective for the serotonin system. A number of antidepressants with increased, but varying, selectivity for the noradrenergic system have become available in recent years, including mirtazapine, bupropion and, most recently, the first truly selective noradrenaline reuptake inhibitor, reboxetine. This review brings together current thinking on the role of noradrenaline in the aetiology and therapy of mood disorders to encourage a rational, evidence-based approach to the treatment of such disorders, and to provide suggestions and guidelines for future research in the area.

Original languageEnglish
Pages (from-to)191-202
Number of pages12
JournalInternational Clinical Psychopharmacology
Issue number4
StatePublished - Jul 2003
Externally publishedYes


  • Antidepressants
  • Anxiety disorders
  • Mood disorders
  • Noradrenaline


Dive into the research topics of 'Noradrenaline in mood and anxiety disorders: Basic and clinical studies'. Together they form a unique fingerprint.

Cite this